CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine

Annals of the New York Academy of Sciences

Volumn 1082, Issue , 2006, Pages 137-150

  Klinman, Dennis M ^a,c   Xie, Hang ^a   Ivins, Bruce E ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adjuvant; Anthrax; CpG oligonucleotide; Protection; Vaccine

Indexed keywords

ANTHRAX VACCINE; CPG OLIGODEOXYNUCLEOTIDE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; BINDING AFFINITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ADSORPTION; FEMALE; GUINEA PIG; IMMUNE RESPONSE; MOUSE; NONHUMAN; RHESUS MONKEY;

MACACA MULATTA;

EID: 33845654330     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1348.030     Document Type: Conference Paper

References (48)

1. HANNA, P. 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225: 13-35.
2. FRIEDLANDER, A.M. & P.S. BRACHMAN. 1998. Anthrax. In Vaccines. S.A. Plotkin & E.A. Mortimer, Eds.: 729-739. W.B. Saunders. Philadelphia, PA.
3. LANE, H.C., J.L. MONTAGNE & A.S. FAUCI. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7: 1271-1273.
4. IVINS, B.E. & S.L. WELKOS. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4: 12-19.
5. IVINS, B.E., S.L. WELKOS, S.F. LITTLE, et al. 1992. Immunization against anthrax with Bacilus anthracis protective antigen combined with adjuvants. Infect. Immun. 60: 662-668.
6. LITTLE, S.F. & B.E. IVINS. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes. Infect. 1: 131-139.
7. WELKOS, S., S. LITTLE, A. FRIEDLANDER, et al. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685.
8. WELKOS, S.L. & A.M. FRIEDLANDER. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5: 127-139.
9. PITTMAN, P.R., P.H. GIBBS, T.L. CANNON & A.M. FRIEDLANDER. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20: 972-978.
10. PITTMAN, P.R., G. KIM-AHN, D.Y. PIFAT, et al. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20: 1412-1420.
11. GEIER, D.A. & M.R. GEIER. 2002. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20: 217-220.
12. READY, T. 2004. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat. Med. 10: 112.
13. DAVIS, H.L., I.I. SUPARTO, R.R. WEERATNA, et al. 2000. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18: 1920-1924.
14. JONES, T.R., N. OBALDIA, R.A. GRAMZINSKI, et al. 1999. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine 17: 3065-3071.
15. VERTHELYI, D., R.T. KENNEY, R.A. SEDER, et al. 2002. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168: 1659-1663.
16. KRIEG, A.M., A. YI, S. MATSON, et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-548.
17. KLINMAN, D.M., A. YI, S.L. BEAUCAGE, et al. 1996. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc. Natl. Acad. Sci. USA 93: 2879-2883.
18. TAKESHITA, F., C.A. LEIFER, I. GURSEL, et al. 2001. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167: 3555-3558.
19. HEMMI, H., O. TAKEUCHI, T. KAWAI, et al. 2000. A toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
20. BALLAS, Z.D., W.L. RASMUSSEN & A.M. KRIEG. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157: 1840-1847.
21. HALPERN, M.D., R.J. KURLANDER & D.S. PISETSKY. 1996. Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha. Cell. Immunol. 167: 72-78.
22. KLINMAN, D.M., K.M. BARNHART & J. CONOVER. 1999. CpG motifs as immune adjuvants. Vaccine 17: 19-25.
23. LIPFORD, G.B., M. BAUER, C. BLANK, et al. 1997. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27: 2340-2344.
24. DAVIS, H.L. 2000. Use of CpG DNA for enhancing specific immune responses. Curr. Top. Microbiol. Immunol. 247: 171-184.
25. MOLDOVEANU, Z., L. LOVE-HOMAN, W.Q. HUANG & A.M. KRIEG. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16: 1216-1224.
26. KRIEG, A.M. & H.L. DAVIS. 2001. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3: 15-24.
27. BAUER, M., K. HEEG, H. WAGNER & G.B. LIPFORD. 1999. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 97: 699-705.
28. HARTMANN, G. & A.M. KRIEG. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164: 944-952.
29. VERTHELYI, D., K.J. ISHII, M. GURSEL, et al. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166: 2372-2377.
30. VOLLMER, J., R. WEERATNA, P. PAYETTE, et al. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34: 251-262.
31. GURSEL, I., M. GURSEL, K.J. ISHII & D.M. KLINMAN. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167: 3324-3328.
32. KLINMAN, D.M., H. XIE, S.F. LITTLE, et al. 2004. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22: 2881-2886.
33. AGRESTI, A. & B.A. COULL. 1996. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 52: 1103-1111.
34. KADOWAKI, N., S. ANTONENKO & Y.J. LIU. 2001. Distinct CpG DNA and polyinosinic-polycytidylic acid ds RNA, respectively stimulate CD11c- type II dendritic precursor and CD11c+ dendritic cells to produce type I interferon. J. Immunol. 166: 2291-2295.
35. LEIFER, C., D. VERTHELYI & D.M. KLINMAN. 2003. Human response to immunostimulatory CpG oligondeoxynucleotides. J. Immunotherapy 26: 313-318.
36. COZON, G.J., J. FERRANDIZ, H. NEBHI, et al. 1998. Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women. Eur. J. Clin. Microbiol. Infect. Dis. 17: 32-36.
37. EGGERS, M., U. BADER & G. ENDERS. 2000. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J. Med. Virol. 60: 324-330.
38. SPARWASSER, T., E. KOCH, R.M. VABULAS, et al. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28: 2045-2054.
39. ROMAN, M., E. MARTIN-OROZCO, J.S. GOODMAN, et al. 1997. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med. 3: 849-854.
40. BRAZOLOT MILLAN, C.L., R. WEERATNA, A.M. KRIEG, et al. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95: 15553-15558.
41. MCCLUSKIE, M.J. & H.L. DAVIS. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161: 4463-4466.
42. BRANDA, R.F., A.L. MOORE, A.R. LAFAYETTE, et al. 1996. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J. Lab. Clin. Med. 128: 329-338.
43. KOVARIK, J., P. BOZZOTTI, L. LOVE-HOMAN, et al. 1999. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162: 1611-1617.
44. DAVIS, H.L., R. WEERANTA, T.J. WALDSCHMIDT, et al. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160: 870-876.
45. XIE, H., I. GURSEL, B.E. IVINS, et al. 2005. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73: 828-833.
46. LITTLE, S.F., B.E. IVINS, P.F. FELLOWS, et al. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-430.
47. GURSEL, M., D. VERTHELYI, I. GURSEL, et al. 2002. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J. Leukocyte Bio. 71: 813-820.
48. KLINMAN, D.M., J. CONOVER & C. COBAN. 1999. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67: 5658-5663.